What is LL-37? cathelicidin origin, mechanism & research.

What LL-37 is, exactly

LL-37 is a 37-amino-acid cationic, amphipathic, alpha-helical antimicrobial peptide. The “LL” in the name refers to the two leucine residues at the N-terminus of the mature peptide. Cationic means it carries a net positive charge at physiological pH, which is central to how it interacts with bacterial membranes. Amphipathic means the molecule has both hydrophobic and hydrophilic faces along its alpha-helix, a structural feature that lets it insert into lipid bilayers.

LL-37 is the sole member of the human cathelicidin family. This is unusual. Most other mammalian species carry multiple cathelicidins (cattle, for example, have several), but humans express only one. That singularity has made LL-37 the focal molecule for human cathelicidin biology and a particularly studied target in innate immunity research.

LL-37 is not stored in the body in its mature form. It exists physiologically as the cleavage product of a larger precursor protein called hCAP-18 (human cationic antimicrobial protein, 18 kDa), encoded by the CAMP gene (cathelicidin antimicrobial peptide). hCAP-18 is what cells synthesize and store. LL-37 is what gets generated, on demand, when host defense is required.

The hCAP-18 to LL-37 origin pathway

Understanding LL-37 means understanding how it is made. The mature peptide is released from hCAP-18 by extracellular proteolytic cleavage, and the protease responsible varies by tissue.

Neutrophils: proteinase 3

In neutrophils, hCAP-18 is stored in secondary (specific) granules. When neutrophils are activated and degranulate at a site of infection or tissue damage, hCAP-18 is released and cleaved primarily by proteinase 3, a serine protease found in primary granules. The two granule populations release their contents in coordinated fashion, which positions proteinase 3 and its substrate in the same extracellular environment at the right moment for cleavage to occur.

Skin: kallikrein 5 (and other proteases)

In skin, the dominant cleavage protease is kallikrein 5 (KLK5), a serine protease that operates in the stratum corneum. Other kallikreins and tissue proteases participate in different anatomical sites. The identity of the cleaving protease matters because aberrant protease activity can produce non-canonical LL-37 fragments with altered, sometimes pathogenic, biological activity, a theme that becomes important in skin disease.

Inducible vs constitutive expression

hCAP-18 expression is constitutive in some cell types (neutrophils carry it as part of their granule load) and inducible in others (epithelial cells, macrophages, and keratinocytes upregulate CAMP expression in response to specific stimuli). The most studied induction signal is vitamin D, which we will return to below. Other inducers include butyrate (a short-chain fatty acid produced by gut bacteria), certain TLR ligands, and inflammatory cytokine signaling.

The compartmentalized storage and tightly regulated cleavage of LL-37 are features, not bugs. The body has evolved to release the active peptide only when and where it is needed, because excess LL-37 is itself biologically consequential.

Why LL-37 is biologically singular

A few features set LL-37 apart from the broader antimicrobial peptide field:

• Sole human cathelicidin. One cathelicidin gene, one mature peptide. Other mammals diversified their cathelicidin repertoire; humans did not. Whatever cathelicidin biology is doing in humans, LL-37 carries the entire load.
• Multifunctional. LL-37 is not just a pore-former that kills bacteria. It is a host-defense signaling molecule that recruits immune cells, modulates dendritic cell function, neutralizes lipopolysaccharide, influences epithelial repair, and shapes cytokine output. The functional repertoire is broader than for most defensins or other classical antimicrobial peptides.
• Vitamin D-regulated. The CAMP gene is one of the most clearly characterized vitamin D target genes in human innate immunity. This connects nutritional status, sunlight exposure, and seasonal physiology directly to a measurable arm of host defense.
• Implicated in disease in both directions. LL-37 deficiency contributes to the infection susceptibility of atopic dermatitis. LL-37 excess contributes to rosacea, psoriasis, and certain autoimmune signaling. Few molecules have such symmetric pathology profiles.

Proposed mechanisms of action

LL-37 acts through several pathways that operate in parallel. None of these are mutually exclusive, and the dominant mode depends on local concentration, tissue context, and the presence of pathogens.

Direct antimicrobial action via membrane disruption

The classical antimicrobial mechanism: LL-37 binds the negatively charged outer surface of bacterial membranes (driven by the cationic-anionic interaction), inserts its amphipathic alpha-helix into the lipid bilayer, and disrupts membrane integrity. The proposed structural model is variously described as a carpet mechanism (the peptide accumulates on the surface and disrupts it like detergent) or a toroidal pore (the peptide and lipid cooperatively form transient pores). The biophysical details have been studied by multiple groups using model membranes and cryo-electron microscopy.

LL-37 has activity against Gram-positive bacteria, Gram-negative bacteria, certain fungi, and enveloped viruses. The viral activity is generally attributed to envelope disruption, similar to the bacterial mechanism. Activity is reduced at physiological salt concentrations, which is one reason in vitro potency does not always translate to in vivo efficacy.

Immunomodulation and chemotaxis

Beyond direct killing, LL-37 acts as a chemoattractant for neutrophils, monocytes, and T cells. This recruitment activity is mediated principally through formyl peptide receptor 2 (FPR2, also called FPRL1), a G protein-coupled receptor expressed on multiple immune cell types. By bringing additional immune cells to the site of infection or injury, LL-37 amplifies the host response. It also modulates dendritic cell maturation and shapes T cell priming.

TLR signaling crosstalk and LPS neutralization

LL-37 binds bacterial lipopolysaccharide (LPS) directly, which can dampen excessive Toll-like receptor 4 (TLR4) signaling and limit endotoxin-driven inflammation. At the same time, LL-37 can complex with self-DNA or RNA in ways that activate TLR9 or TLR7/8 signaling pathways. The directionality is context-dependent. In a sterile or self-nucleic-acid context, this can become problematic, which is part of the autoimmune story.

Wound healing and angiogenesis

LL-37 promotes keratinocyte migration and influences re-epithelialization at wound edges. It also has angiogenic activity, stimulating endothelial proliferation and capillary formation, again primarily through FPR2. These tissue-repair effects are part of the rationale for topical LL-37 research in chronic wound contexts.

Taken together, these mechanisms explain both why LL-37 is interesting as a host-defense molecule and why pharmacological augmentation is harder than it might first appear: pushing on one mechanism inevitably pushes on the others.

The vitamin D link: a defining regulatory feature

One of the most important pieces of LL-37 biology is its regulation by vitamin D. The CAMP gene contains a vitamin D response element (VDRE) in its promoter region. When 1,25-dihydroxyvitamin D (the active hormonal form of vitamin D) binds the vitamin D receptor (VDR), the VDR-RXR heterodimer can bind the VDRE in the CAMP promoter and directly upregulate hCAP-18 expression in macrophages, keratinocytes, and other cell types.

This pathway was characterized in a landmark 2006 Sciencepaper by Liu PT and colleagues (“Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response,” Science 2006;311(5768):1770-3). That work showed that activation of TLR2/1 on human macrophages by Mycobacterium tuberculosis components led to upregulation of the vitamin D receptor and the vitamin D-1-hydroxylase, which together generated local 1,25-dihydroxyvitamin D and induced LL-37 expression. Patients with lower 25-hydroxyvitamin D levels generated less LL-37 in this pathway. This provided a direct mechanistic link between vitamin D status and innate antimicrobial defense.

The vitamin D / cathelicidin axis has shaped substantial downstream research, including work on tuberculosis susceptibility, respiratory tract infections, skin barrier biology, and the seasonal patterns of certain infectious diseases. It is also why vitamin D status is increasingly considered relevant to host defense, separate from its skeletal role.

The dual nature of LL-37: protective in normal amounts, pathogenic when dysregulated

This is the part of LL-37 biology that is most often missed in popular content, and it is the part that matters most for thinking about exogenous administration. LL-37 is not a molecule where “more is better.” Both deficiency and excess produce disease.

Where LL-37 is decreased

• Atopic dermatitis. Lesional atopic dermatitis skin is relatively deficient in LL-37 and human beta-defensin-2 compared with psoriatic skin. This relative deficiency contributes to the elevated risk of bacterial and viral skin infection seen in patients with atopic dermatitis, including eczema herpeticum.
• Some bullous and barrier disorders. Subsets of inherited skin barrier conditions show altered cathelicidin expression patterns that contribute to recurrent infection.

Where LL-37 is increased or aberrantly processed

• Rosacea.Affected skin shows elevated kallikrein 5 activity that produces aberrant LL-37 fragments capable of driving inflammation and vascular dysfunction. The pathology is not simply “more LL-37” but “wrong LL-37.”
• Psoriasis. LL-37 is elevated in psoriatic plaques. It also forms complexes with self-DNA that activate plasmacytoid dendritic cells via TLR9, a mechanism implicated in driving the inflammatory cascade of the disease.
• Rheumatoid arthritis. Synovial tissue and fluid in rheumatoid arthritis show elevated LL-37, and the peptide has been studied as both a marker and a contributor to joint inflammation.
• COPD and chronic airway disease. Cathelicidin expression is altered in chronic obstructive pulmonary disease and other chronic airway inflammation states. The directionality is complex and depends on disease phase.
• Lupus and other autoimmunity. LL-37 binding to self nucleic acids has been linked to autoantigen formation in systemic lupus erythematosus.

The pattern is consistent: LL-37 is essential when the body needs it, in the right amount, in the right place, processed correctly. Outside those conditions, it can become a driver of disease rather than a protector against it. This is the central honesty problem with any approach that frames LL-37 as a benefit one simply administers.

State of the evidence

The LL-37 literature is unusually deep on the basic science side. Thousands of indexed publications cover its structure, mechanism, expression regulation, and role across multiple disease states. The translational picture is thinner. Several engineered LL-37 analogs (designed to retain antimicrobial activity at physiological salt concentrations or to resist proteolytic degradation) have been or remain in clinical development for indications including chronic wound healing, antibiotic-resistant infections, and topical dermatologic conditions.

Among the engineered analogs that have reached clinical evaluation are molecules studied in venous leg ulcer, pressure ulcer, and antibiotic-resistant skin infection contexts. None of these has full regulatory approval as of 2026, and the broader pipeline reflects the difficulty of translating a multifunctional, dose-narrow, context-dependent molecule into a marketable therapeutic.

Native LL-37 itself, as opposed to engineered analogs, has not been the subject of large randomized controlled trials in the United States. The data that exists comes largely from in vitro studies, animal models, and small case series. This is the gap any honest discussion of LL-37 needs to acknowledge.

FDA Category 2 / current FDA classification

Synthetic exogenous LL-37 (the form that would be used in any compounded preparation) is named on the FDA Category-unclassified peptide list released April 15, 2026. This list identifies bulk substances that were removed from the explicit Category 2 prohibited list but not affirmatively placed on Category 1.

Pending Pharmacy Compounding Advisory Committee (PCAC) review, scheduled for July 2026 with the remainder by the end of February 2027, LL-37 sits in a regulatory ambiguity. Some 503A compounding pharmacies are operating on the theory that removal from Category 2 lifts the prohibition. Final FDA disposition is not settled, and Category 2 substances cannot be compounded by 503A pharmacies regardless. PepScribe’s pharmacy standard is 503A-only, and PepScribe treats LL-37 as a consultation-first peptide pending the formal resolution of its category status.

The current FDA classification reflects the FDA’s ongoing evaluation of the safety, characterization, and clinical evidence base for LL-37 as a bulk drug substance for compounding, not a final scientific judgment about cathelicidin biology. The two are separate questions, and conflating them is one of the more common errors in popular content.

Safety considerations: why “more is not better” is unusually literal here

Most peptide therapy discussions treat “more is not better” as a vague caution. With LL-37, the principle has a specific mechanistic basis.

• Cytotoxicity threshold. In vitro, LL-37 becomes cytotoxic to mammalian cells at high concentrations. The therapeutic window between antimicrobial activity and host cell damage is narrower than for most clinical antibiotics, and varies by cell type and conditions.
• Disease-elevation contexts. Several inflammatory and autoimmune conditions are associated with elevated LL-37 (rosacea, psoriasis, rheumatoid arthritis, certain forms of lupus). Augmenting LL-37 in a patient with subclinical or undiagnosed disease in that family is a plausible mechanism for triggering or worsening pathology.
• Self-nucleic-acid signaling. LL-37 forms complexes with self-DNA and self-RNA that can activate TLR pathways in ways relevant to autoimmunity. This is not a hypothetical concern. It is a documented mechanism.
• Proteolytic processing matters. Aberrant cleavage in disease tissue can produce non-canonical fragments with altered biological activity. Exogenous administration of full-length LL-37 does not bypass that biology in a simple way.
• Limited human safety data. Long-term safety data for repeated administration of exogenous LL-37 in non-research populations does not exist at the scale required to support routine clinical use.

The responsible position is neither to dismiss LL-37 as dangerous nor to treat it as an immune supplement. It is to acknowledge that this is a multifunctional, dose-sensitive, context-dependent molecule whose safe and effective therapeutic use, if it is achievable, requires the kind of controlled evaluation that has not yet been completed for native LL-37.

Administration routes that have been studied

Research and small-scale clinical work on LL-37 has explored several administration routes:

• Subcutaneous injection. The most commonly discussed route in compounding contexts. Half-life of native LL-37 in serum is short due to proteolytic degradation and binding to apolipoprotein A-I and other carrier proteins.
• Topical formulations. Studied in wound healing and dermatologic research, including engineered analogs designed for topical stability.
• Nebulized aerosol. Explored in airway research, primarily in early-stage and animal studies of cystic fibrosis and bacterial pneumonia models.
• Engineered analog forms. Many translational programs focus on stabilized analogs or delivery systems rather than native peptide, because native LL-37 is degraded too quickly to serve as a practical drug in many contexts.

There is no internationally standardized clinical dosing protocol for native LL-37. There is no approved LL-37 drug product. Discussion of administration routes here is research context, not prescribing guidance.

Separating signal from noise: how to evaluate LL-37 information

LL-37 content online tends to fall into two camps, both of which miss the actual biology.

Red flags in pro-LL-37 content

• Framing LL-37 as an “immune booster” one simply administers, without acknowledging the disease-elevation contexts
• Claims that LL-37 “treats” chronic Lyme, biofilm-associated infection, COVID-19, or other conditions where the evidence base is insufficient to support treatment claims
• Vendors selling research-grade peptide labeled “not for human consumption” alongside dosing protocols
• Failure to distinguish endogenous LL-37 (which the body regulates carefully) from exogenous administration (which bypasses that regulation)
• Comparison of LL-37 to antibiotics as if it were a direct substitute

Red flags in anti-LL-37 content

• Dismissal of the entire cathelicidin literature as “unproven,” ignoring the depth of basic science evidence on mechanism
• Conflation of “not approved as a drug” with “biologically unimportant”
• Treating regulatory classification as the final scientific judgment rather than a regulatory framework decision

What balanced evaluation looks like

• Acknowledging that LL-37 is a real, multifunctional component of innate immunity with well-characterized regulation
• Acknowledging that excess or dysregulated LL-37 drives disease in several documented contexts, so exogenous administration is not categorically beneficial
• Distinguishing the well-established basic biology from the much thinner translational evidence for native LL-37 as a therapeutic
• Recognizing that engineered LL-37 analogs in clinical development are not the same product as compounded native LL-37 from gray-market sources
• Recognizing that vitamin D status optimization may be the most evidence- supported way to influence cathelicidin biology in many people